Neurochirurgie Nordwest
Kopf- und Wirbelsäulenchirurgie

• Seit 2009: Ärztlicher Leiter Neurozentrum Bellevue in Zürich. Praxistätigkeit im Neurozentrum Enge Zürich und Neurozentrum Aarau. Belegarzt in mehreren Hirslanden Kliniken (Klinik Hirslanden Zürich, Hirslanden Klinik Im Park Zürich, Hirslanden Klinik in Aarau, Andreasklinik in Cham) • 2008 – 2009: Leiter a. i. Neurologisch-Neurochirurgische Poliklinik, Universitätsspital Basel • 2002 – 2008: Oberarzt Neurologie, Universität Basel • 2003 – 2005: Postdoctoral fellow am Department of Neurology, Baylor College of Medicine und Methodist Neurological Institute, Houston, Texas, USA • 1999 – 2002: Assistenzarzt Neurologie, Universität Basel • 1998 – 1999: Assistenzarzt Neurochirurgie, Kantonsspital Aarau • 1997 – 1998: Assistenzarzt Neurologie/Neurorehabilitation, Rehaklinik Rheinfelden • 1995 – 1997: Assistenzarzt Neurologie/Innere Medizin, Schweizer Paraplegikerzentrum, Basel • 1994 – 1995: Assistenzarzt Innere Medizin, Kantonsspital Bruderholz, Basel

• 2010 – 2018: Mitglied des wissenschaftlichen Beirats der Schweizerischen Multiple Sklerose Gesellschaft • 2008 – 2011: Vizepräsident der Schweizerischen Gesellschaft für Muskelkranke (SGMK) • 2007: Habilitation, Universität Basel • 2003: Fähigkeitsausweis Elektroenzephalographie (EEG) der SGKN • 2003: Fähigkeitsausweis Elektroneurographie und Elektromyographie (ENMG) der SGKN • 2002: Facharzt für Neurologie FMH • 2001: Dissertation: Predictive value of T2-lesion volume for the natural course of multiple sclerosis. Universität Basel, Prof. Dr. Ludwig Kappos • 1987 – 1994: Studium der Humanmedizin, Medical University of Gdansk, Polen und Universität Basel, Schweiz Auszeichnungen Recipient of the Sheila Essey Fellowship Award for ALS Research • Fellow of the Swiss National Science Foundation • Fellow of the Fonds zur Förderung des Akademischen Nachwuchses der Universität Basel • Fellow of the Houston Endowment

Prof. Dr. med. Adam Czaplinski ist regelmässig Referent an neurologischen Kongressen in Europa und Amerika und Autor zahlreicher Publikationen. Wissenschaftliche Publikationen in der PubMed-Datenbank.(https://pubmed.ncbi.nlm.nih.gov/?term=Czaplinski+A%5BAuthor%5D) Ocrelizumab in Switzerland – first experiencesSwiss Federation of Clinical Neurosocieties SFCNS, September 2017Interlaken/Switzerland ​ TGA: an altitude sickness?European Academy of Neurology, June 2017Amsterdam/Netherlands ​ Real-life long-term effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohortAmerican Academy of Neurology, April 2017Boston/USA Final results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with RR-MS (SWISSASCENT)ECTRIMS, September 2016London/UK ​ Role of Family Planning in Women of Child-Bearing Age with Multiple Sclerosis (MS) in Switzerland: Results of the Women with MS (WWMS) Patient SurveyAmerican Academy of Neurology April 2016Vancouver/Canada ​ Alemtuzumab: real life experience in SwitzerlandSwiss Federation of Clinical Neurosocieties SFCNS, November 2015Bern/Switzerland ​ Fingolimod treatment induces changes in NK and T helper cell subpopulations and in T cell co-stimulation markers.ECTRIMS, October 2015Barcelona/Spain ​ Stem cells for Amyotrophic Lateral Sclerosis.European Academy of Neurology Meeting, June 2015Berlin/Germany ​ Adherence and compliance in MS therapy.Polish Neurological Society, March 2015Lodz/Poland ​ Alemtuzumab: restoring the immune system.Swiss Neurological Society, October 2014Interlaken/Switzerland ​ Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT).German Neurological Society, September 2014Munich/Germany ​ Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis.ECTRIMS/ACTRIMS Congress, September 2014Boston/USA ​ Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT).European Neurological Society Congress, June 2014Istanbul/Turkey ​ Prolonged-release fampridine in multiple sclerosis: improved ambulatory function by subject-specific changes of the walking pattern.American Academy of Neurology Congress, Mai 2014Philadelphia/USA ​ Swiss post marketing surveillance monitoring quality of life and treatment.Journées de Neurologie de Langue Française, April 2014Strasbourg/France ​ Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT)ECTRIMS Congress, October 2013Copenhagen/Denmark ​ Therapie der Multiplen Sklerose: vom Cortison zur differenzierten Immunomodulation.13th Swiss-Russian general Practicioners Conference, Mai 2013St. Petersburg/Russia ​ Tysabri in der Behandlung der Multiplen SkleroseMS State of The Art 2013, March 2013Lodz/Poland ​ Novel electrochemiluminescence based immunoassay: neurofilament light chain in serum as a marker of axonal damageWilliam Harvey Day, Queen Mary University, October 2012London/United Kingdom ​ A Swiss best practice experience in three different clinical settings of the 6 hour fingolimod observation procedure.ECTRIMS Congress, October 2012Lyon/France ​ Utilization of JC-Virus antibody testing in clinical practice.ECTRIMS Congress, October 2012Lyon/France ​ Tysabri: new data to efficacy and safety.Central European Tysabri Advisory Board (CETAB) Meeting, October 2012Vienna/Austria ​ Fingolimod in daily practice.Swiss Neurological Society (SNG) Meeting, Mai 2012Lugano/Switzerland ​ Update on current treatment strategies in MSAmerican Academy of Neurology (AAN) Meeting, participant, April 2012New Orleans/USA ​ Tysabri: efficacy and safety update.Central European Tysabri Advisory Board (CETAB) Meeting, January 2012Bratislava/Slovakia ​ Personalized treatment strategies in Multiple Sclerosis.ECTRIMS Congress, October 2011Amsterdam/Netherlands ​ Treatment failure: what to do?MS State of the Art, January 2011Lucerne/Switzerland ​ MS therapy update.ECTRIMS Congress, October 2010Göteborg/Sweden ​ Current therapeutic strategies in MS.European Neurological Society Congress (participant), June 2010Berlin/Germany ​ Oral laquinimod for Multiple Sclerosis.TEVA Symposium, Mai 2010Jerusalem/Israel ​ The effect of IFNbeta 1b treatment on cognition in Multiple Sclerosis.Advisory Board meeting, March 2010Rome/Italy ​ Treatment failure, what to do?Multiple Sclerosis State of the Art, Januar 2010Luzern/Switzerland ​ Safety overview of fingolimod.Fingolimod Advisory Board, December 2009Berlin/Germany ​ New oral agents in the therapy of Multiple Sclerosis.Cladribine Advisory Board, November 2009Amsterdam/Netherlands ​ Phasenadaptierte Therapie der Multiplen Sklerose.182. Tagung der Schweizerischen Neurologischen Gesellschaft, Juni 2009Interlaken/Switzerland ​ Application of the Database Controls in Experimental Trials.Annual Meeting of St.Lukes Hospital, April 2009Tokyo/Japan ​ ALS: Can We Predict the Course of Disease?19. Kongress des Wissenschaftlichen Beirates der DGM, March 2009Darmstadt/Germany ​ Natalizumab in daily practice- risks and benefits.11th State of the Art Symposium, January 2009Berne/Switzerland ​ Strategien zur Optimierung der immunomudulatorischen Therapie der MS.Zürcher MS-Roundtable, Oktober 2008Zurich/Switzerland Moderne Therapie der Multiplen SkleroseQuadrimed Kongress, Mai 2008Crans Montana/Switzerland ​ Reconsidering clinical outcomes: relapses, impairment, disability and beyond.Symposium of the European Charcot Foundation, November 2007Fiuggi/Italy Length of prediagnostic period as a predictor of rate of disease progression and survival in ALS.17th Meeting of the European Neurological Societ, June 2007Rhodes/Greece Slower disease progression and prolonged survival in contemporary ALS patients: is the natural history of ALS changing?177. Tagung der Schweizerischen Neurologischen Gesellschaft, Oktober 2006Interlaken/Switzerland ​ Amyotrophic Lateral Sclerosis: Can We Predict the Course of Disease?Kongress der Polnischen Neurologischen Gesellschaft, September 2006Krakow/Poland ​ Predictability of disease progression in amyotrophic lateral sclerosis.XVIth Meeting of the European Neurological Society, Mai 2006Lausanne/Switzerland ​ Slower disease progression and prolonged survival in contemporary ALS patients: is the natural history of ALS changing?58th Annual Meeting of American Academy of Neurology, April 2006San Diego/USA ​ Predictability of disease progression in amyotrophic lateral sclerosis.16th International Symposium on ALS/MND, December 2005Dublin/Ireland ​ Amyotrophic lateral sclerosis: early predictors of prolonged survival.World Congress of Neurology, November 2005Sydney/Australia ​ Application of the Database Controls in Experimental Trials for Amyotrophic Lateral Sclerosis.57th Annual Meeting of American Academy of Neurology, April 2005Miami/USA ​ Flail arm syndrome: a clinical variant of amyotrophic lateral sclerosis.XIIIth Meeting of the European Neurological Society, June 2003Istanbul/Turkey ​ Pathological crying as the initial presenting symptom in amyotrophic lateral sclerosis.XIIIth Meeting of the European Neurological Society, June 2003Istanbul/Turkey Symptomatic care in ALSBasler ALS Symposium, March 2003Basel/Switzerland ​ Predictive value of T2-lesion volume for the natural course of multiple sclerosis.Meeting of the Polish Neurological Society, September 200Poznan/Poland ​ Rapid progressive, sensory-motor demyelinating neuropathy.Xth International Neuromuscular Congress, July 2002Vancouver/Canada ​ Ice pack test for myasthenia gravis: a simple, noninvasive and safe diagnostic method.Xth International Neuromuscular Congress, July 2002Vancouver/Canada ​ The natural course of multiple sclerosis: predictive value of lesion volume in T2-weighted brain MRI.XIIth Meeting of the European Neurological Society, June 2002Berlin/Germany ​ Necrotising vasculitis and isotretinoin.XIIth Meeting of the European Neurological Society, June 2002Berlin/Germany

• Schweizerische Neurologische Gesellschaft (SNG) • Schweizerische Gesellschaft für Klinische Neurophysiologie (SGKN) • European Neurological Society (ENS) • American Academy of Neurology (AAN) • Polish Neurological Society (PTN) • Schweizerische Multiple Sklerose Gesellschaft (SMSG), Wissenschaftlicher Beirat bis 2018 • Schweizerische Gesellschaft für Muskelkranke (SGMK) • Verbindung der Schweizer Ärztinen und Ärzte (FMH)

• Deutsch • Englisch • Polnisch • Russisch